In this Phase 4 , multi-center , double-blind , placebo-controlled trial , young adults ( 18-30 years ) with ADHD were randomized to receive atomoxetine ( 20-50 mg BID , N = 220 ) or placebo ( N = 225 ) for 12 weeks .